BioRestorative Therapies Says FDA Clears BRTX-100 Trial in Chronic Cervical Discogenic Pain

MT Newswires Live
02-27

BioRestorative Therapies (BRTX) said Thursday that the US Food and Drug Administration has cleared its investigational new drug application for BRTX-100 to potentially treat chronic cervical discogenic pain.

BioRestorative Chief Executive Officer Lance Alstodt said the company is planning to carry out a phase 2 study to evaluate BRTX-100's safety and preliminary efficacy in patients with chronic cervical discogenic pain "as soon as is practicable."

Price: 1.87, Change: -0.04, Percent Change: -2.09

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10